TITLE: An Oxazolidinone for Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive Bacteria
CASE NUMBER: C13966
UNMET NEED
Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterized by high mortality rates, is increasing. Current treatments are often ineffective even if used appropriately. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. New therapeutics and new approaches to delivering existing therapeutics are urgently needed to reduce the duration, cost, and side effects of treating TB, MDR-TB, and XDR-TB.
PROBLEM SOLVED
The Inventors have developed a novel oxazolidinone (T145) that has activity against Mycobacterium tuberculosis and Gram positive pathogen Enterococcus faecalis.
T145 inhibits growth of Enterococcus faecalis, methicillin-resistant Staphylococcus aureus and Mycobacterium tuberculosis with sub µg/ml potencies that are potentially therapeutically valuable.
Additionally, T145 minimizes selection of spontaneous resistant mutants, a trait that prolongs longevity of a drug in clinical use.
STAGE OF DEVELOPMENT
The technology is at the preclinical stage of development. The inventors has completed the synthesis of the compound and have growth inhibition and minimum bacterial concentration data in acid fast, gram positive and gram negative pathogens. They also have comparative data for T145 versus current treatment therapeutics. There is also data on drug-drug interaction between T145 and isoniazid and rifampicin two drugs currently use for TB treatment.
DISEASE INDICATION
Infectious Diseases
ASSOCIATED PUBLICATIONS
- PMID:18077175 -
ASSOCIATED REPORTS OF INVENTION (ROIs) AND INTELLECTUAL PROPERTY (IP) FILING NUMBERS
ROI # TITLE
13966 An Oxazolidinone for Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive Bacteria
STATUS PRIORITY DATE IP FILING NUMBERS
Pending 2/17/2016 US 62/296,160
TECHNOLOGY CLASSIFICATION
Primary Category: Therapeutics
Primary Subcategory: Small Molecules
